Literature DB >> 15936575

Automated functional image-guided radiation treatment planning for rectal cancer.

Ilja Frank Ciernik1, Marius Huser, Cyrill Burger, J Bernard Davis, Gabor Szekely.   

Abstract

PURPOSE: Computer tomography-based (CT-based) tumor-volume definition is time consuming and is subject to clinical interpretation. CT is not accessible for standardized algorithms for the purpose of treatment-volume planning. We have evaluated the accuracy of target-volume definition based on the positron emission tomography (PET) data from an integrated PET/CT system with 2-[(18)F]fluoro-2-deoxy-D-glucose (FDG) for standardized target-volume delineation.
MATERIALS AND METHODS: Eleven patients with rectal cancer who were undergoing preoperative radiation therapy (RT) were studied. A standardized region-growing algorithm was tested to replace the CT-derived gross tumor volume by the PET-derived gross tumor volume (PET-GTV) or the biologic target volume (BTV). A software tool was developed to automatically delineate the appropriate tumor volume as defined by the FDG signal, the PET-GTV, and the planning target volume (PTV). The PET-derived volumes were compared with the target volumes from CT.
RESULTS: The BTV defined for appropriate GTV assessment was set at a single peak threshold of 40% of the signal of interest. Immediate treatment volume definition based on the choice of a single-tumor volume-derived PET-voxel resulted in a tumor volume that strongly correlated with the CT-derived GTV (r(2) = 0.84; p < 0.01) and the volume as assessed on subsequent anatomic-pathologic analysis (r(2) = 0.77; p < 0.01). In providing sufficient extension margins from the CT-derived GTV and the PET-derived GTV, to PTV, respectively, the correlation of the CT-derived and PET-derived PTV was sufficiently accurate for PTV definition for external-beam therapy (r(2) = 0.96; p < 0.01).
CONCLUSION: Automated segmentation of the PET signal from rectal cancer may allow immediate and sufficiently accurate definition of a preliminary working PTV for preoperative RT. If required, correction for anatomic precision and geometric resolution may be applied in a second step. Computed PET-based target-volume definition could be useful for the definition of standardized simultaneous internal-boost volumes for intensity-modulated radiation therapy (IMRT) based on biologic target volumes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15936575     DOI: 10.1016/j.ijrobp.2004.12.089

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  14 in total

1.  Joint segmentation of anatomical and functional images: applications in quantification of lesions from PET, PET-CT, MRI-PET, and MRI-PET-CT images.

Authors:  Ulas Bagci; Jayaram K Udupa; Neil Mendhiratta; Brent Foster; Ziyue Xu; Jianhua Yao; Xinjian Chen; Daniel J Mollura
Journal:  Med Image Anal       Date:  2013-05-23       Impact factor: 8.545

2.  Prospective randomized double-blind pilot study of site-specific consensus atlas implementation for rectal cancer target volume delineation in the cooperative group setting.

Authors:  Clifton D Fuller; Jasper Nijkamp; Joop C Duppen; Coen R N Rasch; Charles R Thomas; Samuel J Wang; Paul Okunieff; William E Jones; Daniel Baseman; Shilpen Patel; Carlo G N Demandante; Anna M Harris; Benjamin D Smith; Alan W Katz; Camille McGann; Jennifer L Harper; Daniel T Chang; Stephen Smalley; David T Marshall; Karyn A Goodman; Niko Papanikolaou; Lisa A Kachnic
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-04-18       Impact factor: 7.038

3.  FDG-PET/CT imaging for staging and target volume delineation in conformal radiotherapy of anal carcinoma.

Authors:  Marco Krengli; Maria E Milia; Lucia Turri; Eleonora Mones; Maria C Bassi; Barbara Cannillo; Letizia Deantonio; Gianmauro Sacchetti; Marco Brambilla; Eugenio Inglese
Journal:  Radiat Oncol       Date:  2010-02-06       Impact factor: 3.481

4.  Tumour volume delineation in prostate cancer assessed by [11C]choline PET/CT: validation with surgical specimens.

Authors:  Ralph A Bundschuh; Christina M Wendl; Gregor Weirich; Mathias Eiber; Michael Souvatzoglou; Uwe Treiber; Hubert Kübler; Tobias Maurer; Jürgen E Gschwend; Hans Geinitz; Anca L Grosu; Sibylle I Ziegler; Bernd Joachim Krause
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-02-07       Impact factor: 9.236

5.  A contrast-oriented algorithm for FDG-PET-based delineation of tumour volumes for the radiotherapy of lung cancer: derivation from phantom measurements and validation in patient data.

Authors:  Andrea Schaefer; Stephanie Kremp; Dirk Hellwig; Christian Rübe; Carl-Martin Kirsch; Ursula Nestle
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-07-26       Impact factor: 9.236

Review 6.  18F-FDG PET/CT for image-guided and intensity-modulated radiotherapy.

Authors:  Eric C Ford; Joseph Herman; Ellen Yorke; Richard L Wahl
Journal:  J Nucl Med       Date:  2009-09-16       Impact factor: 10.057

7.  Impact of (18)F-FDG-PET/CT on staging and irradiation of patients with locally advanced rectal cancer.

Authors:  Brigita Paskeviciute; Tobias Bölling; Markus Brinkmann; Ganna Rudykina; Iris Ernst; Lars Stegger; Otmar Schober; Normann Willich; Matthias Weckesser; Stefan Könemann
Journal:  Strahlenther Onkol       Date:  2009-04-16       Impact factor: 3.621

8.  Incorporating PET information in radiation therapy planning.

Authors:  M Macmanus; T Leong
Journal:  Biomed Imaging Interv J       Date:  2007-01-01

9.  Integrated FDG PET/CT: Utility and Applications in Clinical Oncology.

Authors:  Inmaculada Pinilla; Beatriz Rodríguez-Vigil; Nieves Gómez-León
Journal:  Clin Med Oncol       Date:  2008-09-19

10.  Neoadjuvant radiochemotherapy in the treatment of fixed and semi-fixed rectal tumors. Analysis of results and prognostic factors.

Authors:  Robson Ferrigno; Paulo Eduardo Ribeiro dos Santos Novaes; Maria Letícia Gobo Silva; Ines Nobuko Nishimoto; Wilson Toshihiko Nakagawa; Benedito Mauro Rossi; Fábio de Oliveira Ferreira; Ademar Lopes
Journal:  Radiat Oncol       Date:  2006-03-28       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.